Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.76

-2.1%

Dec 30 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (1682)	3/16/2007 1:05:03 PM
From: Jibacoa	Read Replies (2) of 3722

After its large Dec 26 DG & Telcyta's failure to show + clinical results, as well as a negative article by Brian Lawler at the MF, TELK seems to be founding support at the $5 level, apparently with the help of consistent insider buying & its restructuring plans, including reducing its work force by 25%. bigcharts.marketwatch.com Last month, it also announced a deal with SRI to test TELK's C243 for MS & and other autoimmune and inflammatory diseases.(C243, supposedly prevents leukocyte infiltration.) SRI will pay & run the preclinical & other tests with possible FDA application. TELK reserved an option to reacquire the drug development rights. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next